Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity.
about
Oral immunisation as a strategy for enhancing corneal allograft survival.Bench to bedside: new approaches to the immunotherapy of uveitic disease.Key role for IL-21 in experimental autoimmune uveitis.Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific.Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?Functional Modulation of Regulatory T Cells by IL-2.Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis.CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation.Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.Autoimmune uveitis: study of treatment therapies.Nasal administration of retinal antigens maintains immunosuppression of uveoretinitis in cyclosporin-A-treated Lewis rats: future treatment of endogenous posterior uveoretinitis?Immunotolerance and prevention of ocular autoimmune disease.Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases.Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction.Oral tolerance in disease.Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease.T cell mechanisms in experimental autoimmune uveoretinitis: Susceptibility is a function of the cytokine response profileCytokine-dependent Modulation of Oral Tolerance in a Murine Model of Autoimmune Uveitis
P2860
Q32154888-7B3E55A8-FE72-4830-BF1C-94C329796D08Q34993229-F1F0C42B-3413-4C96-B4A9-494A7AF0CD28Q35035122-1E729AC3-221E-4CF0-945D-E9F55719FCE4Q35298191-C083460F-EC52-4334-BB7C-378434EC51D1Q35575081-3304C4B7-91B0-470D-B03E-C5AA92BC87B1Q35830699-3883138E-FAB6-4CD8-B61D-1017F120420CQ36367938-42D5B570-164D-497A-897E-452B169DD1A5Q37303070-EF252839-4814-4998-9339-89F76AFAD4F0Q37522009-B5B0B282-ED9D-4775-8F35-D1317F852376Q38694984-738B88B5-3FF9-4980-B7FE-F538AF2C1922Q40909960-4C3EA1B6-313C-4FCC-BA74-3BAD0B064AE1Q40927838-28ACE657-1E82-4CF9-A7D0-8C5133FB3D6BQ41605290-96DB76F3-6B74-4BD6-8281-84CE64D61E35Q41834495-078184D4-8FF5-45E5-AAED-1BA2389259C4Q43040918-21356413-3981-4894-BBCE-26C90E9CD600Q47346480-E51450A6-AC46-4AF1-860E-2B6AD92B07E3Q57281052-3A9217BD-229D-4CEF-8270-0F45C5FF0E1CQ57281073-3EA657DB-8883-4225-9F4E-AF09E99BBD5F
P2860
Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity.
description
1994 nî lūn-bûn
@nan
1994 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@ast
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@en
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@nl
type
label
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@ast
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@en
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@nl
prefLabel
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@ast
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@en
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@nl
P2093
P2860
P356
P1476
Interleukin-2 treatment potent ...... murine model of autoimmunity.
@en
P2093
Miller-Rivero NE
Nussenblatt RB
P2860
P304
P356
10.1172/JCI117511
P407
P577
1994-10-01T00:00:00Z